LINC00632 and breast carcinoma: This study demonstrated that CDR1as overexpression is associated with adverse chemotherapeutic effects and that CDR1as competitive inhibition of miR‐7 enhanced the sensitivity of drug‐resistant breast cancer cells to cisplatin.